Tocqueville Asset Management L.P. Innoviva, Inc. Transaction History

Tocqueville Asset Management L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$14.32 - $19.88 $89,886 - $124,786	-6,277 Reduced 34.68%	11,824 $175,000
Q1 2022 May 16, 2022	BUY	$15.39 - $20.25 $1,615 - $2,126	105 Added 0.58%	18,101 $350,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $18.72 $49,305 - $58,013	3,099 Added 20.8%	17,996 $310,000
Q3 2021 Nov 15, 2021	BUY	$13.06 - $17.24 $38,527 - $50,857	2,950 Added 24.69%	14,897 $249,000
Q2 2021 Aug 16, 2021	BUY	$11.45 - $13.96 $698 - $851	61 Added 0.51%	11,947 $160,000
Q1 2021 May 17, 2021	BUY	$11.06 - $12.87 $19,941 - $23,204	1,803 Added 17.88%	11,886 $142,000
Q4 2020 Feb 16, 2021	SELL	$9.33 - $12.48 $9,339 - $12,492	-1,001 Reduced 9.03%	10,083 $125,000
Q3 2020 Nov 16, 2020	BUY	$10.33 - $14.49 $114,497 - $160,607	11,084 New	11,084 $116,000

228

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.21B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.